JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36
Benzinga Newsdesk 2 months ago
NewsDowngradesAnalyst RatingsPrice Target
JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.
JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.